Targeted corrective gene conversion (TCGC): Molecular systems for improved correction of gene mutations in muscle

Authors

Robert M. Kapsa, University of WollongongFollow
Joselito M. Razal, University of WollongongFollow
Anita Quigley, University of WollongongFollow
Magdalena Kita, University of WollongongFollow
Marian Todaro, St Vincent’s Hospital
Luveen Bissonauth, St Vincent’s Hospital
Rod Shepherd, University Of SydneyFollow
Simon Moulton, University of WollongongFollow
Mark J. Cook, University of WollongongFollow
Leone Spiccia, Monash University
David L. Officer, University of WollongongFollow
Graeme M. Clark, Latrobe UniversityFollow
Gordon G. Wallace, University of WollongongFollow

RIS ID

32603

Publication Details

Kapsa, R. M., Razal, J., Quigley, A., Kita, M., Todaro, M., Bissonauth, L., Shepherd, R., Moulton, S., Cook, M. J., Spiccia, L., Officer, D. L., Clark, G. M. & Wallace, G. G. (2009). Targeted corrective gene conversion (TCGC): Molecular systems for improved correction of gene mutations in muscle. In 6th Australasian Gene Therapy Society Meeting, 29 Apr- 1 May, Sydney. Journal of Gene Medicine, 11 (9), 856-856.

Abstract

Targeted corrective gene conversion (TCGC) holds much promise as a future therapy for many hereditary diseases in humans, but there still remain significant impediments to effective mutation correction and it is clear that significant work remains to improve TCGC to levels where it can be considered for translation to the clinical setting. Nevertheless, mutation correction frequencies varying between 0.0001% and 40% have been reported using chimeraplasty, oligoplasty, triplex-forming oligonucleotides, and small corrective PCR amplicons. W

Grant Number

ARC/DP0987503

Additional Grant Number

http://purl.org/au-research/grants/ARC/DP0987503